How much profit has Bionomics made this year?
Bionomics has made -436.87 M AUD this year.
Bionomics Net Income 2025
Bionomics Net Income
-436.87 M AUD
Ticker
BNO.AX
ISIN
AU000000BNO5
WKN
936199
In 2025, Bionomics's profit amounted to -436.87 M AUD, a 72.73% increase from the -252.92 M AUD profit recorded in the previous year.
The Bionomics Net Income history
| YEAR | NET INCOME (undefined AUD) |
|---|---|
| 2026e | -28.19 |
| 2025e | -436.87 |
| 2024e | -252.92 |
| 2023e | -35.6 |
| 2022 | -21.76 |
| 2021 | -8.7 |
| 2020 | -7.12 |
| 2019 | -10.36 |
| 2018 | -25.09 |
| 2017 | -6.75 |
| 2016 | -16.59 |
| 2015 | -16.95 |
| 2014 | 3.21 |
| 2013 | -10 |
| 2012 | -3.14 |
| 2011 | -9.36 |
| 2010 | -8.21 |
| 2009 | -6.86 |
| 2008 | -4.78 |
| 2007 | -5.45 |
| 2006 | -5.4 |
| 2005 | -4.63 |
| 2004 | -3.58 |
| 2003 | -4.54 |
Bionomics Revenue, EBIT, Net Income AU000000BNO5 · 936199
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Bionomics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Bionomics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Bionomics’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Bionomics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Bionomics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Bionomics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Bionomics’s growth potential.
Bionomics Revenue, EBIT and net profit per share
| Date | Bionomics Revenue | Bionomics EBIT | Bionomics Net Income |
|---|---|---|---|
| 2026e | 34.3 M undefined | -37.95 M undefined | -28.19 M undefined |
| 2025e | 5.14 M undefined | -58.58 M undefined | -436.87 M undefined |
| 2024e | 8.79 M undefined | -32.01 M undefined | -252.92 M undefined |
| 2023e | 5.14 M undefined | -26.66 M undefined | -35.6 M undefined |
| 2022 | 263,630 undefined | -22.27 M undefined | -21.76 M undefined |
| 2021 | 0 undefined | -8.68 M undefined | -8.7 M undefined |
| 2020 | 46,660 undefined | -4.1 M undefined | -7.12 M undefined |
| 2019 | 906,120 undefined | -8.3 M undefined | -10.36 M undefined |
| 2018 | 3.95 M undefined | -20.84 M undefined | -25.09 M undefined |
| 2017 | 18.61 M undefined | -5.46 M undefined | -6.75 M undefined |
| 2016 | 8.14 M undefined | -17.79 M undefined | -16.59 M undefined |
| 2015 | 6.83 M undefined | -26.13 M undefined | -16.95 M undefined |
| 2014 | 19.92 M undefined | -3.06 M undefined | 3.21 M undefined |
| 2013 | 3.72 M undefined | -17.99 M undefined | -10 M undefined |
| 2012 | 6.83 M undefined | -6.36 M undefined | -3.14 M undefined |
| 2011 | 4.07 M undefined | -9.05 M undefined | -9.36 M undefined |
| 2010 | 3.85 M undefined | -8 M undefined | -8.21 M undefined |
| 2009 | 4.3 M undefined | -6.93 M undefined | -6.86 M undefined |
| 2008 | 7.08 M undefined | -4.83 M undefined | -4.78 M undefined |
| 2007 | 3.43 M undefined | -7.59 M undefined | -5.45 M undefined |
| 2006 | 4.57 M undefined | -5.23 M undefined | -5.4 M undefined |
| 2005 | 3.17 M undefined | -4.31 M undefined | -4.63 M undefined |
| 2004 | 1.98 M undefined | -3.26 M undefined | -3.58 M undefined |
| 2003 | 1.61 M undefined | -4.24 M undefined | -4.54 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2003 | 1.61 M AUD | -4.24 M AUD | -4.54 M AUD |
| 2004 | 1.98 M AUD | -3.26 M AUD | -3.58 M AUD |
| 2005 | 3.17 M AUD | -4.31 M AUD | -4.63 M AUD |
| 2006 | 4.57 M AUD | -5.23 M AUD | -5.4 M AUD |
| 2007 | 3.43 M AUD | -7.59 M AUD | -5.45 M AUD |
| 2008 | 7.08 M AUD | -4.83 M AUD | -4.78 M AUD |
| 2009 | 4.3 M AUD | -6.93 M AUD | -6.86 M AUD |
| 2010 | 3.85 M AUD | -8 M AUD | -8.21 M AUD |
| 2011 | 4.07 M AUD | -9.05 M AUD | -9.36 M AUD |
| 2012 | 6.83 M AUD | -6.36 M AUD | -3.14 M AUD |
| 2013 | 3.72 M AUD | -17.99 M AUD | -10 M AUD |
| 2014 | 19.92 M AUD | -3.06 M AUD | 3.21 M AUD |
| 2015 | 6.83 M AUD | -26.13 M AUD | -16.95 M AUD |
| 2016 | 8.14 M AUD | -17.79 M AUD | -16.59 M AUD |
| 2017 | 18.61 M AUD | -5.46 M AUD | -6.75 M AUD |
| 2018 | 3.95 M AUD | -20.84 M AUD | -25.09 M AUD |
| 2019 | 906,120 AUD | -8.3 M AUD | -10.36 M AUD |
| 2020 | 46,660 AUD | -4.1 M AUD | -7.12 M AUD |
| 2021 | 0 AUD | -8.68 M AUD | -8.7 M AUD |
| 2022 | 263,630 AUD | -22.27 M AUD | -21.76 M AUD |
| 2023e | 5.14 M AUD | -26.66 M AUD | -35.6 M AUD |
| 2024e | 8.79 M AUD | -32.01 M AUD | -252.92 M AUD |
| 2025e | 5.14 M AUD | -58.58 M AUD | -436.87 M AUD |
| 2026e | 34.3 M AUD | -37.95 M AUD | -28.19 M AUD |
Bionomics stock margins AU000000BNO5 · 936199
The Bionomics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Bionomics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Bionomics.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Bionomics's sales revenue. A higher gross margin percentage indicates that the Bionomics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Bionomics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Bionomics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Bionomics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Bionomics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Bionomics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Bionomics Margin History
| Bionomics Gross margin | Bionomics Profit margin | Bionomics EBIT margin | Bionomics Profit margin |
|---|---|---|---|
| 2026e | 0 % | -110.64 % | -82.18 % |
| 2025e | 0 % | -1,139.61 % | -8,499.4 % |
| 2024e | 0 % | -364.33 % | -2,878.39 % |
| 2023e | 0 % | -518.75 % | -692.65 % |
| 2022 | 0 % | -8,447.9 % | -8,253.75 % |
| 2021 | 0 % | 0 % | 0 % |
| 2020 | 0 % | -8,784.83 % | -15,255.66 % |
| 2019 | 0 % | -915.65 % | -1,143.51 % |
| 2018 | 0 % | -527.05 % | -634.44 % |
| 2017 | 0 % | -29.35 % | -36.28 % |
| 2016 | 0 % | -218.43 % | -203.76 % |
| 2015 | 0 % | -382.7 % | -248.26 % |
| 2014 | 0 % | -15.36 % | 16.11 % |
| 2013 | 0 % | -483.6 % | -268.82 % |
| 2012 | 0 % | -93.12 % | -45.97 % |
| 2011 | 0 % | -222.36 % | -229.98 % |
| 2010 | 0 % | -207.79 % | -213.25 % |
| 2009 | 0 % | -161.16 % | -159.53 % |
| 2008 | 0 % | -68.22 % | -67.51 % |
| 2007 | 0 % | -221.28 % | -158.89 % |
| 2006 | 0 % | -114.44 % | -118.16 % |
| 2005 | 0 % | -135.96 % | -146.06 % |
| 2004 | 0 % | -164.65 % | -180.81 % |
| 2003 | 0 % | -263.35 % | -281.99 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2003 | 0 % | -263.35 % | -281.99 % |
| 2004 | 0 % | -164.65 % | -180.81 % |
| 2005 | 0 % | -135.96 % | -146.06 % |
| 2006 | 0 % | -114.44 % | -118.16 % |
| 2007 | 0 % | -221.28 % | -158.89 % |
| 2008 | 0 % | -68.22 % | -67.51 % |
| 2009 | 0 % | -161.16 % | -159.53 % |
| 2010 | 0 % | -207.79 % | -213.25 % |
| 2011 | 0 % | -222.36 % | -229.98 % |
| 2012 | 0 % | -93.12 % | -45.97 % |
| 2013 | 0 % | -483.6 % | -268.82 % |
| 2014 | 0 % | -15.36 % | 16.11 % |
| 2015 | 0 % | -382.7 % | -248.26 % |
| 2016 | 0 % | -218.43 % | -203.76 % |
| 2017 | 0 % | -29.35 % | -36.28 % |
| 2018 | 0 % | -527.05 % | -634.44 % |
| 2019 | 0 % | -915.65 % | -1,143.51 % |
| 2020 | 0 % | -8,784.83 % | -15,255.66 % |
| 2021 | 0 % | 0 % | 0 % |
| 2022 | 0 % | -8,447.9 % | -8,253.75 % |
| 2023e | 0 % | -518.75 % | -692.65 % |
| 2024e | 0 % | -364.33 % | -2,878.39 % |
| 2025e | 0 % | -1,139.61 % | -8,499.4 % |
| 2026e | 0 % | -110.64 % | -82.18 % |
Bionomics Aktienanalyse
What does Bionomics do?
Bionomics Ltd is an Australian biopharmaceutical company specializing in the development of novel therapeutics for the treatment of diseases of the central nervous system and cancer. The company is headquartered in Adelaide, South Australia, and has offices and research facilities in the United States and France. Bionomics was founded in 1998 by Dr. Deborah Rathjen, an experienced biotechnology manager and scientist. The company started as a spin-off from Flinders University in Adelaide, focusing initially on the discovery and development of drug candidates based on novel peptides. In 2002, Bionomics went public, gaining access to capital to expand its research activities and adjust its business strategy. Bionomics operates an integrated pharmaceutical model, ranging from the discovery and optimization of novel therapeutic targets and drugs to clinical development and market launch of pharmaceuticals. The company develops innovative technologies, including the MultiCore platform, to develop peptide-based drugs. Bionomics has two main divisions: CNS therapy and cancer therapy. The CNS therapy division focuses on the development of drugs for the treatment of central nervous system disorders, including schizophrenia, depression, anxiety disorders, neuropathic pain, spinal cord injuries, and other disorders. Bionomics is currently conducting clinical trials to evaluate the effectiveness of its leading drug candidates BN311 and BNO69 in the treatment of depression and anxiety disorders. Bionomics' cancer therapy division focuses on the discovery and development of drug candidates for the treatment of cancer. The company has identified a number of leading preclinical drug candidates based on novel targets, showing promising results in the treatment of breast, lung, ovarian, liver cancer, and other types of cancer. Bionomics has a range of products in development or in clinical stages. The company's leading product is BN311, a drug candidate for the treatment of depression based on Bionomics' MultiCore technology. BN311 has shown efficacy in preclinical studies in the treatment of depression and anxiety disorders and is currently being tested in a phase II clinical trial. BNO69 is another drug candidate from Bionomics based on the same technology. The candidate has been developed for the treatment of anxiety disorders and shows great promise. It has proven effective in preclinical studies and has the potential to revolutionize the treatment of anxiety disorders. The company is also developing drug candidates for the treatment of cancer, including BNC101, BNC105, BNC211, and BNC375. All of these drug candidates are based on novel targets and have shown promising results in preclinical studies. BNC375, a cancer immunotherapy, shows particularly promising results, and the company plans to conduct a phase I clinical trial to evaluate the efficacy of the drug in treating patients with advanced cancer. Overall, Bionomics Ltd is an emerging biopharmaceutical company specializing in the development of new and promising therapeutics for the treatment of diseases of the central nervous system and cancer. Bionomics has developed an integrated pharmaceutical model that supports innovation from discovery to commercialization and has a promising pipeline of drug candidates for the next generation of medications. Bionomics ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Bionomics's Profit Margins
The profit margins of Bionomics represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Bionomics's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Bionomics's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Bionomics's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Bionomics’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Bionomics stock
How has the profit developed compared to last year?
The profit has increased by 72.73% compared to last year increased
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Bionomics publish its earnings?
Bionomics publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Bionomics?
The profits of Bionomics are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Bionomics?
You can learn more about the earnings of Bionomics by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Bionomics pay?
Over the past 12 months, Bionomics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Bionomics is expected to pay a dividend of 0 AUD.
What is the dividend yield of Bionomics?
The current dividend yield of Bionomics is .
When does Bionomics pay dividends?
Bionomics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Bionomics?
Bionomics paid dividends every year for the past 0 years.
What is the dividend of Bionomics?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Bionomics located?
Bionomics is assigned to the 'Health' sector.
Wann musste ich die Aktien von Bionomics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Bionomics from 1/4/2025 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 1/4/2025.
When did Bionomics pay the last dividend?
The last dividend was paid out on 1/4/2025.
What was the dividend of Bionomics in the year 2024?
In the year 2024, Bionomics distributed 0 AUD as dividends.
In which currency does Bionomics pay out the dividend?
The dividends of Bionomics are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Bionomics
Our stock analysis for Bionomics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bionomics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
